Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Acute Myeloid Leukemia Induction with Cladribine: Effects of Age and Leukemia Risk

Martin W. Schoen, MD MPH, Susan K. Woelich, PharmD, BCOP, James T. Braun, Pharm.D, Mark J. Fesler, MD, Paul J. Petruska, MD, Carl E. Freter, MD PhD, Jack M. Lionberger, MD PhD

Blood (2016) 128 (22): 3988.

https://doi.org/10.1182/blood.V128.22.3988.3988

Published: 2016

Journal Articles

Detecting Accumulated Somatic Mutations in Healthy Aged Female Myeloid Cells

Jack M. Lionberger, MD PhD, Ninder K. Panesar, PhD, Bharat Panuganti, Ahmad Rajeh, Carl E. Freter, MD PhD

Blood (2016) 128 (22): 5045.

https://doi.org/10.1182/blood.V128.22.5045.5045

Published: 2016

Journal Articles

Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia

George S. Laszlo, PhD, Jack M. Lionberger, MD, PhD, Kimberly H. Harrington, BS, Chelsea J. Gudgeon, BS, Megan Othus, PhD, Frederick R. Appelbaum, MD, Irwin D. Bernstein, MD, Roland B. Walter, MD, PhD

Blood (2013) 122 (21): 1318.

https://doi.org/10.1182/blood.V122.21.1318.1318

Published: 2013

Journal Articles

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Mazyar Shadman, MD, MPH, Jack M. Lionberger, MD, PhD, Raya Mawad, MD, Ravinder K Sandhu, MD, Carol Dean, RN, Kathleen Shannon-Dorcy, RN, Kyle Wathen, PhD, Bart L Scott, MD, MS, Roland B. Walter, MD, PhD, Pamela S. Becker, MD, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 2622.

https://doi.org/10.1182/blood.V120.21.2622.2622

Published: 2012

Journal Articles

Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not

Ravinder K Sandhu, Jack M. Lionberger, MD, PhD, Megan Othus, PhD, John M. Pagel, MD, PhD, Kathleen ShannonDorcy, RN, PhD, Paul C. Hendrie, MD, PhD, Stephen H. Petersdorf, MD, Pamela S Becker, MD, PhD, Frederick R. Appelbaum, M.D., Elihu H Estey, MD

Blood (2011) 118 (21): 1497.

https://doi.org/10.1182/blood.V118.21.1497.1497

Published: 2011

Journal Articles

Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in De Novo Adult AML

Jack M. Lionberger, MD, PhD, Kathleen Shannon Dorcy, RN, MN, Ph.C, Carol Dean, RN, Nathan Holm, BS, Bart Lee Scott, MD, J. Kyle Wathen, PhD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2011) 118 (21): 1552.

https://doi.org/10.1182/blood.V118.21.1552.1552

Published: 2011

NARROW

Acute Myeloid Leukemia Induction with Cladribine: Effects of Age and Leukemia Risk

Detecting Accumulated Somatic Mutations in Healthy Aged Female Myeloid Cells

Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not

Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in De Novo Adult AML

Email alerts

ASH Publications

American Society of Hematology

Acute Myeloid Leukemia Induction with Cladribine: Effects of Age and Leukemia Risk

Detecting Accumulated Somatic Mutations in Healthy Aged Female Myeloid Cells

Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not

Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in De Novo Adult AML

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only